Behr, Jürgen
Nathan, Steven D. http://orcid.org/0000-0002-6270-1617
Costabel, Ulrich http://orcid.org/0000-0003-2804-9511
Albera, Carlo http://orcid.org/0000-0002-0334-869X
Wuyts, Wim A.
Glassberg, Marilyn K. http://orcid.org/0000-0003-1990-6614
Haller, Harold Jr
Alvaro, Giuseppe
Gilberg, Frank
Samara, Katerina
Lancaster, Lisa
Clinical trials referenced in this document:
Documents that mention this clinical trial
M32 Effect of pirfenidone on all-cause mortality (acm) and forced vital capacity (fvc) in idiopathic pulmonary fibrosis (ipf) patients with low fvc and/or low dlco: analysis of pooled data from ascend and capacity
https://doi.org/10.1136/thoraxjnl-2017-210983.454
M27 Effect of pirfenidone on breathlessness as measured by the ucsd-sobq score in patients with idiopathic pulmonary fibrosis (ipf) with moderate lung function impairment
https://doi.org/10.1136/thoraxjnl-2017-210983.449
Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical Studies
https://doi.org/10.1007/s12325-023-02565-3
Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials
https://doi.org/10.1136/bmjresp-2015-000105
Genome-wide association study across five cohorts identifies five novel loci associated with idiopathic pulmonary fibrosis
https://doi.org/10.1136/thoraxjnl-2021-218577
Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry
https://doi.org/10.1136/bmjresp-2018-000331
Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials
https://doi.org/10.1136/bmjresp-2018-000323
Funding for this research was provided by:
F. Hoffmann-La Roche
Universitätsklinik München
Article History
Received: 6 April 2023
Accepted: 18 May 2023
First Online: 30 June 2023